-Frontline The Land Acquisition Bill runs into a roadblock as political parties fail to reach an agreement on the substantive features of the draft Bill or on the amendments proposed. The efforts of the United Progressive Alliance government to broker a consensus on the Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement Bill, 2012, which has been pending for over a year, have not paid off not because...

-Live Mint Reimbursing schools that reserve 25% seats for underprivileged children may end up costing the govt about Rs.16,000 cr The central government is faced with the prospect of a large bill to pay for the implementation of one of the key elements of the right to education (RTE) legislation-reimbursing private schools that reserved 25% of their seats for underprivileged children-even as the 31 March deadline for most of the law's other...

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...